Human normal immunoglobulin (Grifols)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameHuman normal immunoglobulin (Grifols)
Drug Alias NameFlebogamma 5% DIFIGSC 20% - GrifolsIntravenous normal Human immunoglobulin – GrifolsImmune Globulin Subcutaneous 20% Caprylate/ChromatographyFlebogamma 10% DIF +[12] 
ClassificationBiologics > Blood components
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Immunologic Deficiency SyndromesPrimary Immunodeficiency Diseases +[8] 
Global Approved IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, IdiopathicMucocutaneous Lymph Node Syndrome +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/01/01
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGrifols Sa
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Grifols Sa
Inactive CompaniesGrifols Therapeutics LlcGrifols Biologicals Llc
Active IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, IdiopathicMucocutaneous Lymph Node Syndrome +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Primary Immunodeficiency DiseasesAlzheimer Disease +[4] 

Other Information

ATC CodeJ06BA
Related LinksN/A